BlackRock Fund Advisors’s Concert Pharmaceuticals, Inc. CNCE Stock Holding History

BlackRock Fund Advisors’s Portfolio CNCE Stock Details CNCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$5.62M	Sell	545,973 -213,029	-28%	-$1.95M	﹤0.01%	2878
2016 Q3	$7.67M	Buy	759,002 +46,938	+7%	+$513K	﹤0.01%	2618
2016 Q2	$8M	Buy	712,064 +25,029	+4%	+$319K	﹤0.01%	2533
2016 Q1	$9.38M	Buy	687,035 +15,701	+2%	+$226K	﹤0.01%	2388
2015 Q4	$12.7M	Sell	671,334 -45,084	-6%	-$980K	﹤0.01%	2309
2015 Q3	$13.4M	Buy	716,418 +27,437	+4%	+$466K	﹤0.01%	2240
2015 Q2	$10.3M	Buy	688,981 +439,331	+176%	+$6.69M	﹤0.01%	2482
2015 Q1	$3.78M	Buy	249,650 +16,746	+7%	+$234K	﹤0.01%	2965
2014 Q4	$3.1M	Buy	232,904 +214,118	+1,140%	+$2.76M	﹤0.01%	3068
2014 Q3	$237K	Sell	18,786 -1,360	-7%	-$13.2K	﹤0.01%	3416
2014 Q2	$203K	Sell	20,146 -162,494	-89%	-$1.57M	﹤0.01%	3485
2014 Q1	$2.46M	Buy	+182,640	New	+$2.58M	﹤0.01%	3116

Other funds holding CNCE

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

ISL

Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Numeric Investors Boston, Massachusetts $13.7B AUM 28.88% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

SAM

Senzar Asset Management New York $34.7M AUM 0.56% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

BlackRock Fund Advisors's CNCE Position: Q4 2016 in Review

BlackRock Fund Advisors reduced its Concert Pharmaceuticals, Inc. (CNCE) stake by 28% in Q4 2016, selling an estimated $1.95M and leaving 545,973 shares worth $5.62M. The position accounts for ﹤0.01% of the portfolio, ranked #2878.

BlackRock Fund Advisors first reported a position in CNCE in Q1 2014 and has held it in 12 quarters since. The position peaked at $13.4M in Q3 2015. 89 funds tracked by Wall St. Rank hold CNCE as of Q4 2016.

BlackRock Fund Advisors held 545,973 shares of Concert Pharmaceuticals, Inc. worth $5.62M as of Q4 2016.
BlackRock Fund Advisors sold 213,029 Concert Pharmaceuticals, Inc. shares in Q4 2016, an estimated $1.95M.
Concert Pharmaceuticals, Inc. made up ﹤0.01% of BlackRock Fund Advisors's portfolio in Q4 2016, its #2878 holding.
BlackRock Fund Advisors first reported a position in Concert Pharmaceuticals, Inc. in Q1 2014 and has held it in 12 quarters since.
BlackRock Fund Advisors's Concert Pharmaceuticals, Inc. position peaked at $13.4M in Q3 2015.
89 funds tracked by Wall St. Rank held Concert Pharmaceuticals, Inc. as of Q4 2016.

Based on BlackRock Fund Advisors's 13F filing for Q4 2016, filed 10 Feb 2017.